Summit joins the global colorectal fight
The pivotal Harmoni-GI3 study has started enrolling patients.
Gastrointestinal is next for pumitamig
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Exelixis claims a next-generation colorectal win
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
